Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18–64 years
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234830/

Highlights
•Publication promotes vaccination to fight against the COVID-19 pandemic.
•We assessed the benefits and risks per million male population of age 18–64 stratified by age groups.
•Results show CVmRNA vaccine benefits outweigh risks for all model scenarios.
•If the trend of pandemic changes significantly or a new variant emerges, benefits-risks must be reassessed.

https://i.imgur.com/eFT0zQj.jpg